Biological function of the BCR-ABL oncogene is dependent on its activated tyrosine kinase. Mutations that inactivate the SRC homology 2 (SH2) domain, the GRB2-binding site in BCR, or the major autophosphorylation site of the kinase domain selectively disrupt downstream signaling but not tyrosine kinase activity. Despite a loss of fibroblast transformation activity, all three mutants retain the ability to render hematopoietic cell lines growth factor independent and transform primary bone marrow cells in vitro. In vivo tests of malignant potential reveal a most critical role for signals dependent on the BCR-ABL SH2 domain. The efficiency of both fibroblast and hematopoietic transformation by BCR-ABL is strongly affected by increased dosage of the SHC adapter protein, which can connect tyrosine kinase signals to RAS. The BCR-ABL oncogene activates multiple alternative pathways to RAS for hematopoietic transformation.
Introduction
Deregulated RAS signaling is associated with a wide variety of human leukemia (Janssen et al., 1987; Sawyers and Denny, 1994) . The mechanisms of RAS activation in leukemia include the following: RAS point mutations, inactivating mutations of RAS-GAP molecules, or the signals from tyrosine kinase oncogenes (reviewed by Sawyers and Denny, 1994) . Multiple SH2 domain-containing adapter molecules can connect tyrosine kinase signals to the RAS signaling pathway (reviewed by Pawson, 1994) .
BCR-ABL is a chimeric tyrosine kinase oncogene (reviewed by Kurzrock et al., 1988 ) generated by the reciprocal t(9;22) (q34;q11) translocation that fuses BCR gene sequence upstream of the second exon of the c-ABL gene (Kurzrock et al., 1988) . Two BCR-ABL proteins, P210 and P185, are associated with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), respectively. BCR-ABL can transform fibroblast and hematopoietic cells in vitro (Lugo et al., 1990; McLaughlin et al., 1989) . P210 or P185 can recapitulate a CML-like disease in mice (Daley et al., 1990; Elefanty et al., 1990; Kelliher et al., 1990; Gishizky et al., 1993) . BCR-ABL provides the initiating event, but additional genetic changes are required for the full malignant phenotype (Kurzrock et al., 1988; McLaughtin et al., 1989) .
The tyrosine kinase activity of the BCR-ABL molecule is one essential determinant of its transforming potency (Lugo et al., 1990; McLaughlin et al., 1989) . Mutations that inactivate tyrosine kinase activity block transformation for multiple ABL alleles (reviewed by Rosenberg and Witte, 1988) . Higher BCR-ABL tyrosine kinase dosage correlates with a quantitative increase in transforming potency in multiple assays (Lugo et al., 1990; McLaughlin et al., 1989) .
The connection between the BCR-ABL tyrosine kinase signal and downstream signal transduction pathways is provided by multiple functional domains (Muller et al., 1991; McWhirter and Wang, 1991; Pendergast et al., 1993a Pendergast et al., , 1993b Afar et al., 1994 ). Mutations of a major autophosphorylation site (Y793F) within the catalytic domain (Pendergast et al., 1993a; Afar et al., 1994) , the GRB2-binding site (Y177F) within BCR (Pendergast et al., 1993b; Pull et al., 1994) , or the SH2 domain (R552L) (Afar et al., 1994) block the ability of BCR-ABL to stimulate growth of rodent fibroblast cells in soft agar without significantly altering the activity of the kinase. Autophosphorylated Y793 of P185 BCR-ABL may provide a docking site for SH2-containing cellular proteins (Pendergast et al., 1993a; Afar et al., 1994) . Mutation of the arginine residue within the conserved FLVRES motif of the ABL SH2 domain (R552L) blocks binding to phosphotyrosine-containing proteins (Mayer et al., 1992) . Mutation of Y177 blocks the direct interaction between the GRB2 adapter molecule and BCR-ABL (Pendergast et al., 1993b; Pull et al., 1994) . This mutation has previously been reported to impair BCR-ABL activation of the RAS signal transduction pathway in fibroblast cells and to block hematopoietic cell transformation (Pendergast et al., 1993b) .
We now demonstrate that BCR-ABL activates multiple signaling pathways to RAS in hematopoietic cells. A BCR-ABL mutant that is unable to bind the GRB2 adapter molecule retains the ability to transform hematopietic cells in vitro and full malignant potential in vivo. Activation of the SHC adapter provides an alternative signal from BCR-ABL to RAS in hematopoietic cells. Increased SHC dosage can complement both fibroblast and hematopoietic transformation by BCR-ABL.
Results

BCR-ABL Mutants Blocked for Fibroblast Transformation Cause Factor-lmdependent Growth of Myeloid and Lymphoid Cell Lines
Point mutations of BCR-ABL were constructed that uncouple signaling to downstream pathways, but leave the BCR-ABL catalytic activity intact. Mutations of an autophosphorylation site (Y793F) within the kinase domain, of an autophosphorylation site (Y177F) within BCR, and of the SH2 domain (R552L) have all been shown to block BCR-ABL transformation of rodent fibroblast cells (Afar et al., 1994; Pendergast et al., 1993a Pendergast et al., , 1993b . Combinations of double-and triple-point mutations were also gener- ated within P185 BCR-ABL by site-directed mutagenesis ( Figure 1A ). Helper-free retroviral stocks were prepared by transient transfection of BCR-ABL plasmids along with the retroviral Psi-packaging vector in 293 T cells (Muller et al., 1991 ; Pear et al., 1993; Afar et al., 1994) . Following infection of Rat1 fibroblast cells with recombinant retroviruses, similar levels of protein expression for wild type and each of the P185 mutants was detected by anti-ABL Western blotting (Figure 1 B) . Anti-phosphotyrosine Western blots show that BCR-ABL mutant-encoded proteins contain similar levels of phosphotyrosine as does wild-type BCR-ABL ( Figure  1C ). BCR-ABL molecules mutated at the SH2 domain (R552L) are tyrosine autophosphorylated in vivo with a similar efficiency as other BCR-ABL molecules, but demonstrate a decrease in the phosphorylation of a prominent 62 kDa cellular protein band ( Figure 1 D; Ellis et al., 1990; Afar et al., 1994) .
The ability of tyrosine kinase oncogenes to render hematopoietic cell lines growth factor independent is a measure of their ability to activate RAS (Satoh et al., 1991) . BCR-ABL permits factor-independent growth of a variety of hernatopoietic cell lines (Daley and Baltimore, 1988; Young et al., 1991 ; Pendergast et al., 1993a) . Interleukin-7 (IL-7)-dependent early B-lymphoid cells (clone H, Young et al:, The ability of clone H or DAGM hematopoietic cells to be rendered factor-independent for growth following infection by a variety of BCR-ABL retroviruses was determined. Wells were scored positive that demonstrated the outgrowth of factor-independent cells after 14 days postplating. Rat1 cells were infected using the same retroviral stocks, and the average number of macroscopic colonies (>0.75 mM) observed after 21 days in agar are indicated.
1991) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-dependent myeloid cells (DAGM, Rennick et al., 1987) were infected with retroviral stocks. At 2 days postinfection, growth factor was removed from the media. Any of the BCR-ABL single-point mutants can cause factor-independent growth of DAGM or clone H cells with a similar efficiency as wild-type BCR-ABL (Table 1 ; Pendergast et al., 1993a) . No single mutation inactivates a domain that is essential for growth factor independence.
Hematopoietic Transformation Analysis of BCR-ABL Mutants In Vitro and In Vivo
Fresh murine bone marrow was infected with matched retroviral stocks of wild-type and BCR-ABL point mutantencoding retroviruses. Following infection, bone marrow cells were plated under conditions that support the growth of transformed early B-lymphoid cells (Whitlock and Witte, 1981) . At 21 days following infection, bone marrow cultures infected with retrovirus encoding the neomycin resistance gene alone develop an adherent stromal cell layer but few nonadherent cells (<1 × 104 cells/ml) ( Table 2 ; McLaughlin et al., 1989) . BALB/c bone marrow infected with retrovirus stocks encoding BCR-ABL wild type or single-point mutants demonstrated an outgrowth of transformed early B-lymphoid cells (>1 x 106 cells/ml) within 21 days (Table 2 ). The efficiency with which the BCR-ABL single-point mutants transform bone marrow is slightly diminished relative to wild-type BCR-ABL, as demonstrated by a decrease in the ratio of transformed cultures (Table 2) . Nevertheless, each of the P185 singlepoint mutants can transform pre-B-lymphoid cells in this assay. The only discernible difference observed was a delay of between 1-3 days for mutant transformed cells to reach confluence (>1 x 108 cells/ml). Double-and triplepoint mutants of BCR-ABL failed to transform bone marrow cells (Table 2) . Cells transformed by wild-type BCR-ABL and single-point mutants demonstrated similar level of BCR-ABL expression and cellular phosphotyrosinecontaining proteins (data not shown). The Y177F GRB2-binding mutant of BCR-ABL was previously reported to be unable to transform naive bone mar- Fresh BALB/c bone marrow was infected with BCR-ABL retroviral stocks normalized to give equivalent expression following acute infection into fibroblast cells. Cultures were scored positive that demonstrated >1 x 106 nonadherent cells/ml at 21 days following infection. The number of cultures positive over total represents the total from at least three separate experiments for each BCR-ABL allele tested. None of the double-point mutants nor the triple-point mutant of BCR-ABL were capable of giving outgrowths of transformed B-lymphocytes.
row using a similar in vitro transformation assay (Pendergast et al., 1993b) . However, in our assays, this mutant clearly scores positive for bone marrow transformation ( Figure 2A ; Table 2 ). To exclude the possibility that a reversion of the GRB2-binding site mutation (Y177F) occurred, the association between the GRB2 adaptor molecule and BCR-ABL was examined ( Figure 2B ). When BCR-ABL proteins are immunoprecipitated from transformed bone marrow cell extracts, GRB2 associates with the wild-type BCR-ABL kinase, but not the Y177F mutant ( Figure 2B) . These results clearly demonstrate that a direct interaction between BCR-ABL and the GRB2 adaptor molecule is not essential for in vitro transformation of murine bone marrow.
The most stringent test of BCR-ABL oncogenic potential is the ability to cause leukemia in mice. One strategy is to first transform bone marrow cells in vitro, followed by injection into mice (Whitlock and Witte, 1981; McLaughlin et al., 1989; KeUiher et al., 1991) . The advantage of this approach is that the observed latency period until leukemia is shorter (Whitlock and Witte, 1982; McLaughlin et al., 1989) .
When ABL transformed B-lymphoid cells are grown in culture for greater than 8 weeks, they lose their dependence on a stromal cell layer for growth and demonstrate a higher potency for tumor formation in animals (Whitlock and Witte, 1981) . BCR-ABL wild-type and point mutantinfected transformed bone m arrow cells were passaged in culture for more than 20 weeks. There was no discernible difference in the ability of bone marrow cells transformed by different BCR-ABL alleles to grow in vitro when cultured in the absence of a stromal feeder layer.
To avoid any host immune response, CB-17 scidlscid mice served as recipient animals (reviewed by Dick et al., 1991) . BCR-ABL transformed cell lines were injected subcutaneously (1 x 10 B cells/site) bilaterally into the flanks of CB-17 scidlscid mice. Within 10-21 days, the wild-type, GRB2-binding site mutant (Y177F), and autophosphorylation site mutant (Y793F) transformed bone marrow cells (B) BCR-ABL proteins were immunoprecipitated from transformed bone marrow cells using polyclonal antibodies raised against the ABL carboxyl terminus. Immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis followed by immunoblotting with anti-ABL or anti-GRB2 (Transduction Labs) monoclonal antibodies. The P185 Y177F mutant protein does not associate with the GRB2 molecule in transformed cells.
gave rise to local tumors at the site of injection (>1 cm diameter). Recipient mice developed dramatic splenomegaly and massive lymphadenopathy, with spleen sizes typically 5-10 times larger than for control mice. Bone marrow cells transformed by wild-type BCR-ABL, the GRB2-binding (Y177F) mutant, or the autophosphorylation (Y793F) mutant demonstrated an equivalent highly malignant phenotype in vivo (Table 3) . Despite the long-term culture of cells transformed by the BCR-ABL SH2 mutant in vitro, there was a dramatically reduced malignant phenotype when the cells were introduced into CB-17 scidlscid mice (Table 3) . Cells transformed by wild-type BCR-ABL rapidly gave rise to tumors (10-14 days) bilaterally in all mice injected. In contrast, BCR-ABL R552L SH2 mutant-expressing cells caused tumors in only two recipient mice, at only a single site of injection per mouse. The latency period for tumor formation in these two animals was increased to 10-12 weeks for BCR-ABL R552L SH2 transformed cells (Table 3 ). The BCR-ABL SH2 mutant transformed cells are poorly tumorigenic, demonstrating that efficient malignant transformation in vivo requires an intact SH2 domain.
Redundant Signaling from BCR-ABL to RAS Involves the SHC Adapter Molecule
In the absence of direct GRB2 binding to BCR-ABL, additional signals to RAS through SH2 domain-containing adaptor molecules may take place. The SHC and CRK-L molecules are likely candidates, since they have been implicated in RAS activation (Pelicci et al., 1992; Ravichandran et al., 1995; ten Hoeve et al:, 1994; Nichols et al., 1994) and become tyrosine phosphorylated in BCR-ABL transformed hematopoietic cells. The SHC adapter when tyrosine phosphorylated binds the GRB2 molecule and stimulates GRB2-SOS complex formation (Ravichandran et al., 1995) . The amino acid sequence surrounding the high affinity GRB2-binding site (Y317) of SHC (Salcini et al., 1994 ) is identical to the GRB2-binding site (Y177) of BCR-ABL (Pendergast et al., 1993b; PuU et al., 1994) , suggesting that the two sites might be functionally redundant. To demonstrate alternative connections between BCR-ABL and RAS activation, we examined SHC phosphorylation and SHC-GRB2 complex formation. Cell lysates from DAGM cells rendered growth factor independent by different BCR-ABL mutants or the parental DAGM cell line were immunoprecipitated with SH C-specific antisera. Anti-SHC immunoprecipitates demonstrate that SHC is expressed in all of the cell lines at equivalent levels (Figure 3, top) . SHC is tyrosine phosphorylated in each of the BCR-ABL transformed cell lines, including the P185 Y177F GRB2-binding mutant, but not in the parental cell lines (Figure  3, middle) . Tyrosine-phosphorylated SHC proteins stably associate with the GRB2 adaptor molecule in these cells (Figure 3, bottom) . The formation of SHC-GRB2 complexes in BCR-ABL transformed cells occurs without direct BCR-ABL/GRB2 association. These results demonstrate that there are alternate pathways from BCR-ABL to RAS activation in hematopoietic cells.
Increased SHC Dosage Complements BCR-ABL For Fibroblast And Hematopoietic Transformation
To test whether increased expression of the SHC molecule can complement the P185 Y177F GRB2 mutant for fibroblast transformation, both genes were introduced simulta- neously into Rat1 cells. Retroviral constructs were prepared that have the control neomycin resistance gene or the wild-type human SHC cDNA whose transcription is driven bythe retroviral long terminal repeat (LTR) promoter (Figure 4) . Transcription of different BCR-ABL alleles was driven by the thymidylate kinase promoter (Figure 4 ). Retrovirus encoding both SHC and P185 Y177F GRB2 mutant demonstrate a rescue of the transformed phenotype resulting in nearly 10 times the number of colonies and with a larger average colony size as well as increased acidification of the medium as compared to the P185 Y177F GRB2-binding mutant with the control neomycin gene (Figure 4) . A 5-to 10-fold increase in SHC expression over endogenous levels, as monitored by Western blotting (data not shown), was not sufficient for soft agar colony formation in Rat1 cells (Figure 4) . SHC overexpression thus supersedes the requirement for an intact GRB2-binding site in BCR-ABL. Elevated SHC expression may function to increase the dosage of RAS signaling in the absence of a direct BCR-ABL/GRB2 interaction.
Retrovirus encoding both SHC and BCR-ABL were utilized to infect fresh bone marrow ( Figure 5 ). Transformed pre-B-lymphoid cells were counted at 9, 13, and 16 days following infection ( Figure 5 ). Retrovirus encoding both SHC and the P185 (Y177F) GRB2 mutant demonstrated a shortened time to confluence ( Figure 5A ). Wild-type BCR-ABL also induced faster growth with increased SHC dosage ( Figure 5B) with BCR-ABL for hematopoietic transformation and can stimulate the rate of transformation by a BCR-ABL GRB2-binding mutant.
Discussion
Genetic and biochemical evidence strongly implicates RAS signaling in BCR-ABL transformation (Mandanas et al., 1993; ten Hoeve et al., 1994; Pull et al., 1994; Sawyers et al., 1995) . Dominant negative forms of RAS block BCR-ABL transformation of both fibroblast and hematopoietic cells (Sawyers et al., 1995) . Connections between BCR-ABL and RAS signaling are likely, therefore, to be essential for transformation. The GRB2 molecule constituitively associates with the RAS nucleotide exchange factor SOS and has been implicated in RAS activation (Lowenstein et al., 1992; Skolnik et al., 1993; Chardin et al., 1993) . A direct interaction between the GRB2 adapter molecule and BCR-ABL had been previously reported to be essential for BCR-ABL activation of the RAS signaling pathway for fibroblast and hematopoietic transformation (Pendergast et al., 1993b) . In direct contrast, we demonstrate that GRB2 binding to BCR-ABL via phosphorylated Y177 is not required for the RAS-dependent phenomena of growth factor independence, for hematopoietic transformation of bone marrow, or for in vivo tumor formation (Figure 2 ; Tables 2 and 3 ).
In concert with our finding, the v-ABL oncogene can effectively transform hematopoietic cells, yet does not directly bind the GRB2 molecule (data not shown). Similarly, the recently described translocation product TEL-ABL generates an activated tyrosine kinase oncogene that lacks a discernible GRB2-binding site (Papadopoulos et al., 1995) . These results all show that signaling to RAS via a Since activation of RAS is essential for BCR-ABL transformation, alternate pathways to RAS activation must exist in the absence of GRB2 binding. SHC-GRB2 complexes are present in hematopoietic cells transformed by the BCR-ABL GRB2-binding mutant (Figure 3 ). Increased dosage of the SHC adapter molecule complements the P185 Y177F GRB2-binding mutant for fibroblast transformation and stimulates the rate of hematopoietic transformation. These results demonstrate that there are multiple redundant signaling pathways from BCR-ABL to RAS. Blocking any single connection between BCR-ABL and RAS is therefore not likely to impair hematopoietic transformation.
The best examples of redundancy in signaling to RAS are provided by receptor tyrosine kinase molecules. An epidermal growth factor receptor mutant lacking all known autophosphorylation sites is unable to bind to the GRB2 molecule, yet can still induce SHC phosphorylation and RAS activation in fibroblast cells (Gotoh et al., 1994) . Targeted disruption of the insulin receptor substrate 1 (Irsl) gene in mice provides further compelling evidence for redundancy in signaling to RAS (Tamemoto et al., 1994; Araki et ai., 1994) . IRS1 is the major substrate of the insulin receptor and can bind to a number of SH2-containing adapter molecules, including GRB2. Mice lacking IRS1 demonstrate no morphological abnormalities (Tamemoto et al., 1994; Araki et al., 1994) . Insulin stimulation of liver cells from these mice results in SHC tyrosine phosphoryla-tion and activation of the RAS-MAP kinase pathway (Tamemoto et al., 1994) .
Our results also demonstrate that fibroblast and hematopoietic cells are not equivalent for transformation by BCR-ABL. While the BCR-ABL Y793F and Y177F mutants are unable to transform fibroblast cells, they can readily transform bone marrow cells in vitro and demonstrate a highly malignant phenotype in vivo. In addition, the BCR-ABL SH2 domain appears to transmit a critical signal for malignant growth in vivo. Recently, Songyang et al. (1995) have demonstrated that cytoplasmic tyrosine kinase domains select peptides with similar sequences as their adjoining SH2 domains. This suggests that the SH2 domain may function to make the BCR-ABL tyrosine kinase signal more effective for transformation.
Overexpression of c-MYC can effectively rescue the SH2 domain mutant of BCR-ABL for fibroblast cell transformation (Afar et al., 1994) . The cell cycle regulatory protein cyclin D1 has also been recently shown to rescue the BCR-ABL SH2 mutant for fibroblast transformation and in vivo tumorigenesis (Afar et al., 1995) . These results suggest that a number of cell cycle components including MYC and cyclin D1 act downstream of an SH2-dependent signaling pathway for BCR-ABL malignant transformation. BCR-ABL mutants that are impaired for transformation or in vivo malignant growth thus provide us with a useful tool to examine signaling. The selective complementation of different BCR-ABL mutants by signaling molecules should permit us to define genetically pathways involved in BCR-ABL hematopoietic transformation.
Experimental Procedures
Plasmid Constructions and Preparation of Viral Stocks
The pSRaMSVtkneo vector (Muller et al., 1991) was used to produce helper-free retroviral stocks by transient overexpression in 293 T cells (Pear et al., 1993; Afar et al., 1994) . Cloning of the different P185 BCR-ABL mutants into the retroviral vector has been previously described (Afar et al., 1994; Pendergast et al., 1993b) . To generate combinations of double-and triple-point mutants of P185 BC R-ABL, we took advantage of a unique Kpnl site located at position (2054) within P185 BCR-ABL. The SHC cDNA was cloned into the pSRaMSVtk vector at the upstream EcoRI site. Different forms of BCR-ABL were cloned at the Notl restriction site downstream of the thymidylate kinase promoter. Viral stocks were quantitated by acute infection of 1 x 10 s Rat1 fibroblast cells. At 48 hr postin fection, BCR-ABL genome transfer was assesed by expression of BCR-ABL proteins. Viral stocks were normalized to give approximately equivalent protein expression for the various BCR-ABL mutants.
Growth Factor Independence Assays and Soft Agar Assays
Rat1 fibroblast transformation by BCR-ABL mutants was quantitated via a soft agar transformation assay as previously described (Lugo et al., 1990) . Growth factor independence assays of I L-7-dependent clone H cells or GM-CSF-dependent DAGM myeloid cells (Rennick et al., 1987) were performed as previously described (Pendergast et al., 1993a) . In brief, 1 x 106 hematopoietic cells or 1 x 10 s fibroblast cells were infected with retroviruses encoding the indicated BCR-ABL forms. Infections were performed for 3 hr at 37°C with 3.0 ml of virus stock. At 2 days postinfection, 5 x 10" fibroblast cells per 6 cm dish were plated, in duplicate, onto soft agar containing 20% serum. After 3 weeks of growth in agar, colonies larger than 0.75 mm in size were scored as positive. Following infection, hematopoietic cell lines were grown in appropriate growth factor for 2 days. Cells were then washed twice in media to remove exogenous growth factors and plated in 96-well dishes at a density of 1 x 104 cells/well. At 2 weeks postinfection, wells that demonstrated an outgrowth of factorindependent cells were scored positive.
Western Blotting and Immunoprecipitations
Expression of BCR-ABL mutants and analysis of tyrosine-phosphorylated proteins was done on 15 ~g of total cell extracts from Rat1 fibroblast cells or from transformed hematopoietic cells. Anti-ABL Western blots were probed with 21-24 monoclonal antibody (Oncogene Sciences). Anti-phosphotyrosine blots were probed with 4G10 monoclonal antibody (U BI). SHC and GRB2 antibodies were purchased from Transduction Labs. For immunoprecipitation of BCR-ABL protein, 5 x 106 transformed high density bone marrow cells were lysed in 0.5 ml of lysis buffer (10 mM HEPES {pH 7.4], 150 mM NaCI, 10% glycerol, 1 mM NaVO4, and 1 mM PMSF). For immunoprecipitation of SHC proteins, 5 x 108 parental DAGM cells or cells that had been rendered growth factor independent by various BCR-ABL mutants were lysed in lysis buffer. Lysates were clarified by centrifugation for 15 rain at 14,000 x g in a refrigerated microcentrifuge. Lysates were incubated with pEX5, a carboxy-terminal, anti-ABL polyclonal antibody (Konopka et al., 1984) or with 1.5 ~g of affinity-purified polyclonal SHC antibody for 2-4 hr on ice. Immune complexes were collected by the addition of protein A-Sepharose beads for 2 hr with constant shaking at 4°C, followed by washing 3-4 times in lysis buffer.
Murine Bone Marrow Transformation Assay
Fresh bone marrow from the tibias and femurs of 3-to 4-week-old BALB/c mice was infected with matched retroviral stocks of different BCR-ABL mutants and plated at a density of 5 x 106 cells per 6 cm dish as previously described (McLaughlin et al., 1989) . The number of nonadherent cells was counted 21 days post infection. A plate was scored positive if the cell count exceeded 1 x 106 cells/ml.
Tumor Challenges
Cell lines were generated from bone marrow cells transformed in vitro by wild type or BCR-ABL mutants. Cell lines were selected that could grow in the absence of a stromal feeder layer. Transformed lymphoid cells (1 x 106) were injected subcutaneously per site into the flanks of nonirradiated CB-17 scid/scid mice. Immune-deficient CB-17 scid/ scid mice were bred and maintained in a laminar flow tower in a defined flora colony. Mice were observed for the growth of tumors at the local site site of injection. Mice that developed tumors (>1 cm in diameter) were autopsied and examined for the signs of metastatic growth of transformed bone marrow cells.
